Propylene Glycol Alginate Sodium Sulfate (PSS): The First Oral Heparinoid Marine Drug—A Pharmacological and Clinical Review
Propylene glycol alginate sodium sulfate (PSS) is the first oral heparinoid marine drug, derived from brown algal alginic acid and marketed in 1986. Its core pharmacology, including anticoagulation, lipid-lowering, microcirculation improvement, and neuroprotection, makes it an affordable oral option for chronic ischemic cardiovascular and cerebrovascular diseases. Pharmacological studies have also revealed anti-inflammatory, anti-fibrotic, anti-metastatic, and FGF/FGFR-activating effects. Notably, these activities can be independently modulated by molecular weight and M/G ratio, enabling activity-specific structural optimization, guiding the development of safer derivatives. This review summarizes PSS’s R&D, mechanisms, clinical applications, and safety, aiming to inform precision medication strategies and inspire similar drug development.
Authors
- Xuan Xia
- 李佳裕
- Guanhua Du
- Caixia Hao
- Yupeng Wang
- Quancai Li
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
- Marine Biomedical Research Institute of Qingdao (CN)
- Ocean University of China (CN)
Publication Details
- Journal
- International Journal of Drug Discovery and Pharmacology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.53941/ijddp.2026.100024
- Primary Topic
- Seaweed-derived Bioactive Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.00